Skip to main content

Table 4 Literature review of the investigated inflammation- and fibrosis-associated genes in bronchiolitis obliterans (BO), idiopathic pulmonary fibrosis (IPF) and organizing pneumonia (OP) humans and mice

From: Organizing pneumonia in mice and men

References

Pulmonary disease: no. of cases/controls

Materials

Investigated parameters

Methods

Human

Magnan et al. [16]

BO: 6/7

BAL (TBB) from lung transplant recipients

TGFB1, IL-6, TGFB2

Immunoassay for cytokine determination

Immunohistochemistry

Taghavi et al. [19]

BO: 38/34

BAL (TBB) from lung transplant patients

MMP2, MMP8, MMP9, TIMP1, TIMP2, BAL cell count

ELISA

Ramirez et al. [22]

BO: 13/21

BALF from lung transplant recipients

IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-γ, GM-CSF, TNF-α, TGFB1, fibronectin gene expression, gelatinolytic activity

Multiplex Bead Immunoassay

ELISA

Gelatin zymography

Jonigk et al. [10]

BO: 12/12

Explanted lung allografts

BMP4, BMPR2, LOX, MMP14, PLAU, CCL5, THBS1, TIMP1, TGFB1, COL3A1, TIMP2, TGFBR2, BMP2, PLA1, EDN1, COL1A2, COL4A1

RNA microarray (45 target genes)

Mouse

Majeski et al. [23]

OP:

Reovirus 1/L induction of intraluminal fibrosis

Il-6, Ccl2

RiboQuant multiprobe ribonuclease protection assay

ELISA

Phillips et al. [18]

IPF: 3–6 mice for each treatment group (bleomycin/saline)

Bleomycin mouse model

Cxcr4, Cxcl12, Col1, CD45, CD34, α-SMA, Col3

FACS, ELISA, qRT-PCR,

Immunohistochemistry

Chen et al. [17]

BO: 4/4

Heterotopic tracheal transplantation from TIMP-1 null (-/-) mutation and wild-type (TIMP-1 +/+) mice

Βeta-actin, Mmp3, Mmp7, Mmp9, Mmp12, Timp1, Timp2, Timp3, Timp4

Immunohistochemistry

qRT-PCR

Xu [24]

BO: 6/6

Heterotopic tracheal transplantation

Cxcr4

Immunohistochemistry

Immunofluorescence

Western blot

Vittal et al. [20]

IPF:

Bleomycin mouse model

Tgfb1, FAK (PTK2), PKB/Akt

qRT-PCR

Western blot

Immunohistochemistry

Shi et al. [21]

IPF:

Bleomycin mouse model

Tgfb1, Smad3

Immunohistochemistry

  1. Significantly regulated genes are highlighted in italics
  2. ACTB beta-actin, BAL bronchoalveolar lavage, BMP bone morphogenetic protein, BMPR bone morphogenetic protein receptor, CCL CC chemokine ligand, CD40LG CD40 ligand, Cxcr4 chemokine (C-X-C motif) receptor 4, Cxcl12 chemokine (C-X-C motif) ligand 12, ECP eosinophilic cationic protein, FAK (PTK) focal adhesion kinase (protein tyrosine kinase), FasL Fas ligand, FGF1 fibroblast growth factor 1, FOXP3 forkhead box P3, GM-CSF granulocyte macrophage colony-stimulating factor, HLA human leukocyte antigen, IFN interferon, IL interleukin, IP10 interferon gamma-induced protein 10, LTA lymphotoxin-α, LOX lysyl oxidase, MCP1 monocyte chemotactic protein, MIP macrophage inflammatory protein, MIG (CXCL9) monokine induced by gamma interferon, MMP matrix metalloproteinase, MPO myeloperoxidase, NG neutrophilic granulocytes, PDGFB platelet-derived growth factor subunit B, PLAU plasminogen activator (urokinase), RPL13A 60S ribosomal protein L13a, sCD30 soluble CD30, SLPI secretory leukocyte protease inhibitor, Smad Sma and Mad-related protein family members, sRAGE soluble receptor for advanced glycation end products, TGF transforming growth factor, THBS1 thrombospondin-1, TIMP1 tissue inhibitor of matrix metalloproteinases 1, TNFα tumor necrosis factor, alpha, TNFSF7 TNF ligand superfamily member 7, VEGF vascular endothelial growth factor, YKL-40 chitinase-like glycoprotein